Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Phase I Solid Tumor PD-1 Inhibitor Study Enrolled 78 Days Early

An Oncology Case Study

Read the Case Study

About the Case Study

Pharm-Olam was contracted to manage and recruit four sites for Phase I, first-in-human research of a PD-1 drug treatment for solid tumor malignancies. The study consisted of 18 patients. These participants were monitored for drug safety, PK, and efficacy. Six cohorts were tested on six different doses or treatment frequencies.

Pharm-Olam reached target enrollment 77 days ahead of schedule. The study needed to be escalated to reflect a high recruitment rate. The cohort management and monitoring strategy evolved to support the quick enrollment and the source data verification that stemmed from it.

 

Program Overview: Phase I, First-in-man
Indication: Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) in Adult Subjects with Advanced Refractory Solid Tumor Malignancies


Sites & Locations: 4 sites in the United States



 

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us